Table 3 |
|||
|
The comparative gene expression profiles of preclinical arthritis rats and Bhsp65-tolerized rats for the subsets of genes that play a role in the pathogenesis of arthritisa |
|||
|
Fold change (compared to baseline) |
|||
|
Gene symbol |
Gene name |
Preclinical arthritis rats |
Bhsp65-tolerized rats |
|
|
|||
|
Costimulatory molecule |
|||
|
Cd86 |
CD86 molecule |
# |
+2.06* |
|
Cytokine or cytokine receptor |
|||
|
Ifi47 |
Interferon γ-inducible protein 47 |
+2.44* |
+2.37* |
|
Ifi27l1 |
Interferon α-inducible protein 27-like 1 |
+2.14* |
# |
|
Il1a |
Interleukin 1α |
+4.61* |
+3.21* |
|
Il1b |
Interleukin 1β |
# |
+3.05* |
|
Lta |
Lymphotoxin α (TNF superfamily, member 1) |
# |
+2.10* |
|
Socs1 |
Suppressor of cytokine signaling 1 |
+3.67* |
+3.14* |
|
Socs3 |
Suppressor of cytokine signaling 3 |
# |
+2.44* |
|
Ifng |
Interferon γ |
+10.00* |
+9.09* |
|
Il12rb2 |
Interleukin 12 receptor β2 |
+4.08* |
+3.89* |
|
Il10 |
Interleukin 10 |
# |
+2.07* |
|
Il33 |
Interleukin 33 |
-2.50* |
# |
|
LOC301289 |
Similar to interleukin 17 precursor (IL-17) |
+16.74* |
# |
|
Il17f |
Interleukin 17F |
+7.86* |
# |
|
RGD1561292 |
Interleukin 22 |
+7.26* |
# |
|
Chemokine/receptor |
|||
|
Cxcl10 |
Chemokine (C-X-C motif) ligand 10 |
+8.02* |
+8.15* |
|
Ccr5 |
Chemokine (C-C motif) receptor 5 |
+2.22* |
+2.50* |
|
Cxcr7 |
Chemokine (C-X-C motif) receptor 7 |
-2.47* |
# |
|
Angiogenesis |
|||
|
Wars |
Tryptophanyl RNA synthetase |
+2.29* |
+2.17* |
|
Vegfa |
Vascular endothelial growth factor A |
# |
+2.21* |
|
Nos2 |
Nitric oxide synthase 2, inducible |
+7.83* |
+4.77* |
|
Others |
|||
|
Bst2 |
Bone marrow stromal cell antigen 2 |
+2.90* |
+3.04* |
|
Slc7a2 |
Solute carrier family 7 (cationic amino acid transport) |
+4.98* |
+4.15* |
|
|
|||
|
aBhsp65: mycobacterial heat shock protein 65. The genes listed were selected using false discovery rate < 5% and ≥2-fold change as the cutoff; +, upregulation; -, downregulation (- number); *significant compared to the corresponding baseline expression; #not significant compared to the corresponding baseline expression. |
|||
|
Yu et al. Arthritis Research & Therapy 2011 13:R143 doi:10.1186/ar3457 |
|||